Creatmed has been selected for the national-level "Reveal and Lead" innovation project for nucleic acid drugs! It is the only project in the field of circular RNA!

This time, the project selected for Curemed was jointly developed by Dr. Zuo Chijian's team, which has completed the underlying patent layout for circular RNA,

The Clean-PIE circularization framework developed by it utilizes ORF or IRES for circularization, completely breaking the patent monopoly of international circular RNA leading companies,

Meanwhile, due to the fact that circular RNA does not require capping or tailing, nor nucleotide modification, it successfully avoids various patent restrictions associated with linear mRNA,

It has opened up a new path for the industrialization of the mRNA field. At the same time, it has broken through the bottleneck of large-scale production and purification of circular RNA,

High-purity circular RNA is obtained through revolutionary purification methods, and a GMP production system that meets IND application requirements is fully established.

The preclinical pharmacodynamic study of the intratumoral injection project for cytokines encoded by circular RNA has been fully completed, and it has demonstrated good anti-tumor immune therapy effects.

The circular RNA of this project has completed three batches of GMP-grade production and toxicological pre-experiments on non-human primates. It is expected to proceed with the IND application in the first quarter of 2023.

Meanwhile, the clinical study initiated by the researchers of this project has passed ethical approval and is about to achieve First-in-Human clinical drug administration, making it the world's first circular RNA clinical project.

As the only project selected in the field of circular RNA, Curemed also hopes to leverage the platform of the National Center for Biomedical Technology Innovation,

Through this "Challenge and Leadership" event, we aim to connect resources and strengths from all sectors, promote the development of the domestic circular RNA (cRNA) drug industry, and contribute to the innovative development of RNA drugs in China.

[About Kerui Maide]

Suzhou Kerui Maide Biomedical Technology Co., Ltd. is located on the 1st and 2nd floors of Building C, Tengfei Science and Technology Park, Suzhou Industrial Park,

A 4000㎡ laboratory that meets GMP standards has been established, and a 10000㎡ GMP production plant and R&D platform are currently under construction.

Curemed focuses on the research and development of new-generation circular mRNA nucleic acid drugs, and has applied for more than 30 invention patents for core platform technologies in the circular mRNA field,

Multiple PCT international patents and 2 software copyrights. The new cyclization framework Clean-PIE system, independently developed by Curemed, does not require the introduction of exogenous sequences,

Precise and efficient cyclization, lower immunogenicity, and higher expression efficiency and duration. We have developed an LNP nucleic acid delivery system with independent intellectual property rights,

The core patent has been granted, enabling the mass production of LNP nucleic acid drugs.

The circular mRNA technology with independent intellectual property rights is leading domestically and comparable internationally.

Curemed aims to build a comprehensive circular mRNA nucleic acid pharmaceutical platform,

Actively develop product pipelines for infectious diseases, tumor immunology, protein replacement, gene therapy, cell therapy, and other fields.

To meet the huge clinical treatment needs. Currently, we are actively advancing the IND application for circular mRNA drugs.